A dosing error by researchers on the AstraZeneca-Oxford University Covid vaccine trial led to a huge boost in the jab's success rate, the pharmaceutical company's vice president has revealed. 'That, in essence, is how we stumbled upon doing half dose-full dose (group),' he told Reuters. While the Pfizer and Moderna jabs will play a vital role, the Oxford vaccine is much better suited to mass immunisation involving billions of people. The Oxford vaccine can be stored and transported in a normal fridge, while the other two require deep freeze. And the Oxford jab is based on well-established technology, meaning it is easier to manufacture at large scale.

Source: Daily Mail November 24, 2020 00:59 UTC